Gemeinschaftspraxis Haematologie Onkologie

The Gemeinschaftspraxis Haematologie Onkologie is conducting studies that focus on colorectal cancer, rectal cancer and HER2‑positive gastrointestinal tumors. Trials aim to test new targeted agents, assess the value of circulating tumor DNA for guiding adjuvant therapy, and compare modern chemotherapy combinations with standard regimens to improve survival and organ preservation.

• Adjuvant therapy based on ctDNA status after resection of stage II colon cancer
• Combination of tucatinib, trastuzumab and chemotherapy for HER2‑positive metastatic colorectal cancer
• KRAS G12C inhibitor plus anti‑EGFR therapy in KRAS‑mutated advanced colorectal adenocarcinoma
• Post‑resection/ablation chemotherapy versus observation in metastatic colorectal disease
• Short‑course radiotherapy versus chemoradiotherapy with organ‑preservation endpoints for high‑risk rectal cancer

These investigations reflect the site’s commitment to advancing treatment options for patients with digestive system malignancies and to integrating molecular diagnostics into everyday practice.

Research at the Dresden clinic includes a broad range of blood‑related disorders such as chronic myeloid leukemia, myelodysplastic syndromes, polycythemia vera, and autoimmune cytopenias. The studies primarily evaluate novel inhibitor combinations, assess deep molecular responses, and explore therapies that can reduce transfusion dependence or improve blood counts.

• Asciminib versus nilotinib for newly diagnosed chronic phase CML
• Venetoclax plus short‑course azacitidine in acute myeloid leukemia unsuitable for standard induction
• Imetelstat versus placebo for transfusion‑dependent low‑risk MDS
• Rusfertide for hematocrit control in polycythemia vera
• Ianalumab added to eltrombopag for primary immune thrombocytopenia

By targeting molecular pathways and immune mechanisms, the site seeks to deliver therapies that achieve durable remissions and better quality of life for patients with hematologic diseases.

The center’s oncology portfolio spans solid tumors and lymphoid malignancies, including breast cancer, multiple myeloma, and various forms of lymphoma. Clinical trials are designed to test innovative drug combinations, evaluate biomarker‑driven strategies, and compare new regimens with established standards to extend progression‑free and overall survival.

• PI3K inhibitor in‑addition to HER2‑targeted therapy for HER2‑positive, PIK3CA‑mutant early breast cancer
• MeziVd versus PVd in relapsed/refractory multiple myeloma
• Acalabrutinib combined with R‑CHOP for untreated non‑GCB diffuse large B‑cell lymphoma
• Mosunetuzumab plus lenalidomide versus rituximab‑lenalidomide in follicular lymphoma
• Elacestrant plus olaparib versus olaparib alone for HR‑positive, HER2‑negative metastatic breast cancer with BRCA mutations

These efforts underscore the site’s role in delivering cutting‑edge cancer care, from early‑stage disease to heavily pre‑treated populations, while incorporating molecular profiling to personalize therapy.